Abstract

Patients with a broad range of neoplastic diseases will be entered on treatment protocols developed by Cancer and Leukemia Group B (CALGB). These protocols, used under carefully defined conditions, seek to extend our knowledge regarding the best use of established drugs, new chemotherapeutic agents and other treatment modalities in the management of malignant diseases. Individuals from this institution take part in pilot studies, protocol design and group-wide studies in the evaluation of treatment programs. In particular, investigators from Dartmouth have been interested in new approaches to acute myelogenous leukemia, small cell carcinoma of the lung (SCCL) and the use of antithrombotic agents in the treatment of neoplasms. A panel of unique monoclonal antibodies (MoAb) which are cytotoxic to AML cells has been developed at Dartmouth by Dr. Edward Ball for ex vivo treatment of bone marrow from patients with AML in second or third remission prior to autologous bone marrow transplantation (ABMT). On the basis of pilot data from Dartmouth and Scripps (UCSD), two new CALGB protocols will study the use of these antibodies in purging bone marrow prior to ABMT in AML. Dr. William North has continued his studies of neurophysins associated with SCCL. He has developed polyclonal and monoclonal antibodies to these substances and is studying their diagnostic potential. In addition, Dr. Ball has made highly specific MoAb to SCCL. These are presently being used by the Pathology Committee to re-classify this group of diseases, and efforts are underway to utilize these antibodies as therapeutic tools in vivo and ex vivo. Dr. Leo Zacharski has been the PI of two randomized cooperative VA trials studying the efficacy of Warfarin and an antiplatelet agent (RA-233) in the treatment of various tumors. The first trial indicated the Warfarin doubled the median survival in patients with SCCL, and the second trial has shown that RA-233 prolongs survival in patients with non-small cell lung cancer limited to one hemithorox. The beneficial effect of Warfarin has been confirmed in the most recent CALGB protocol (#8084) for extensive SCCL. The present CALGB protocol for limited SCCL (#8433) is testing Warfarin in a controlled trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA004326-30
Application #
3555799
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1993-03-31
Budget Start
1988-04-01
Budget End
1989-03-31
Support Year
30
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
Dartmouth College
Department
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755

  Publications

Lawson, David H; Lee, Sandra; Zhao, Fengmin et al. (2015) Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl J Clin Oncol 33:4066-76
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Wang, Xiaofeng; Owzar, Kouros; Gupta, Pankaj et al. (2014) Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol 78:1005-13
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98

Showing the most recent 10 out of 108 publications